Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting the Th17 pathway in psoriasis.

M Merle Elloso1, Mireia Gomez-Angelats, Anne M Fourie

  • 1Janssen Research & Development, LLC, San Diego, CA, USA.

Journal of Leukocyte Biology
|September 11, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis.

Journal of medicinal chemistry·2025
Same author

Guselkumab binding to CD64<sup>+</sup> IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.

Frontiers in immunology·2025
Same author

IL-23 tunes inflammatory functions of human mucosal-associated invariant T cells.

iScience·2025
Same author

The mode of action of IL-23 in experimental inflammatory arthritic pain and disease.

Arthritis research & therapy·2024
Same author

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans.

Scientific reports·2024
Same author

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.

Frontiers in immunology·2024

The Th17 pathway, involving interleukin-17A (IL-17A)-producing CD4(+) T cells, is increasingly recognized for its role in psoriasis. This review examines evidence and therapies targeting this crucial immune pathway in psoriasis.

Area of Science:

  • Immunology
  • Dermatology

Background:

  • The traditional Th1/Th2 CD4(+) T cell paradigm now includes the distinct Th17 lineage.
  • Th17 cells produce IL-17A, a key proinflammatory cytokine.
  • Growing evidence links IL-17A and the Th17 pathway to psoriasis pathogenesis.

Purpose of the Study:

  • To review preclinical and clinical evidence implicating Th17 cells in psoriasis.
  • To summarize therapeutic strategies targeting the Th17 pathway in psoriasis.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of clinical trial data.
  • Examination of approved and investigational therapies.

Main Results:

  • Substantial evidence supports Th17 cell involvement in psoriasis.

Related Experiment Videos

  • Targeting the IL-17A/Th17 pathway shows therapeutic promise.

    • Conclusions:

    • The Th17 pathway is a significant factor in psoriasis.
    • Targeting Th17 cells offers effective treatment options for psoriasis.